Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease. 1990

A B Thomson
Division of Gastroenterology, University of Alberta, Edmonton, Canada.

Numerous environmental and genetic factors have been implicated in the pathogenesis of peptic ulcer disease. Although the cause of this disorder has not been established, acid pepsin has been acknowledged at least as a permissive factor in its development. More important, inhibition of nocturnal or 24-hour intragastric acidity is predictably associated with ulcer healing. Famotidine 40 mg at bedtime maintains approximately one-third of pH readings at or above 3.5, reduces pepsin activity, and has no adverse effect on mean total serum gastric concentrations after one week of therapy. In addition, the effect of this dose of famotidine is comparable to ranitidine 300 mg at bedtime and predicts comparable rates of ulcer healing. Thus, monitoring of intragastric pH levels may be useful in identifying potent healers of peptic ulcer disease and in selecting optimal doses or timing of drug administration. Studies of famotidine using such measurements have suggested that this new H2-receptor antagonist is comparable to ranitidine in the healing of duodenal ulcers.

UI MeSH Term Description Entries
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D015738 Famotidine A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Famotidine Hydrochloride,MK-208,Pepcid,YM-11170,MK 208,MK208,YM 11170,YM11170

Related Publications

A B Thomson
January 1995, Journal of clinical gastroenterology,
A B Thomson
January 1986, Scandinavian journal of gastroenterology. Supplement,
A B Thomson
February 1992, Hepato-gastroenterology,
A B Thomson
August 1967, Klinicheskaia meditsina,
A B Thomson
January 1990, Journal of clinical gastroenterology,
A B Thomson
May 1991, Gastroenterology,
A B Thomson
October 1985, Scandinavian journal of gastroenterology,
A B Thomson
March 1963, Hospital (Rio de Janeiro, Brazil),
Copied contents to your clipboard!